Deutsches Krebsforschungszentrum (DKFZ)

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial (2022) Wick A, Sander A, Koch M, Bendszus M, Combs S, Haut T, Dormann A, et al. Journal article The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis (2022) Spohn SKB, Farolfi A, Schandeler S, Vogel MME, Ruf J, Mix M, Kirste S, et al. Journal article Integrated radiogenomics analyses allow for subtype classification and improved outcome prognosis of patients with locally advanced HNSCC (2022) Meneghetti AR, Zwanenburg A, Linge A, Lohaus F, Grosser M, Baretton GB, Kalinauskaite G, et al. Journal article DNA methylation-based classification of sinonasal tumors (2022) Jurmeister P, Glöß S, Roller R, Leitheiser M, Schmid S, Mochmann LH, Payá Capilla E, et al. Journal article Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients (Breast Cancer Research, (2022), 24, 1, (69), 10.1186/s13058-022-01567-3) (2022) Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BA, Becher H, Blomqvist C, et al. Journal article, Erratum PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients (2022) Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, et al. Journal article EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy (2022) Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn BV, Barinoff J, et al. Journal article Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes (2022) Herbig M, Jacobi A, Wobus M, Weidner H, Mies A, Kraeter M, Otto O, et al. Journal article Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis (2022) Unglaub JM, Schlenk RF, Hanoun M, Reinhardt HC, Middeke JM, Schaefer-Eckart K, Steffen B, et al. Conference contribution Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (> 55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) (2022) Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, et al. Conference contribution